Anupriya Agarwal, PhD

Curtis Lachowiez, MD

Kelly Bolton, MD, PhD

Courtney DiNardo, MD

Olivia Lucero, MD

Andrew Frelinger, PhD

“Investigating clinical efficacy and mechanism of low-dose sirolimus as an early intervention strategy for RUNX1-FPD”

  • Principal Investigator: Anupriya Agarwal, PhD – Oregon Health & Science University

  • Team Principal: Courtney DiNardo, MD, MSCE – The University of Texas MD Anderson Cancer Center

  • Co-Investigators: 

    • Curtis Lachowiez, MD, and Olivia Lucero, MD – Oregon Health & Science University

    • Kelly Bolton, MD, PhD – Washington University School of Medicine in St. Louis

    • Andrew Frelinger, PhD – Boston Children’s Hospital

Building on Dr. Agarwal’s longstanding RUNX1-FPD research, this project will expand an ongoing clinical trial evaluating whether low-dose sirolimus, an FDA-approved drug with anti-inflammatory effects, could serve as an early intervention strategy for individuals with RUNX1-FPD.

The team will study safety and examine how the therapy impacts inflammation, immune signaling, and mutation burden to generate key data to guide future leukemia prevention trials.